Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
14.68 SEK | -2.13% | -5.53% | +3.53% |
Sales 2023 | - | Sales 2024 * | 104M 9.73M | Capitalization | 1.68B 157M |
---|---|---|---|---|---|
Net income 2023 | -311M -29.08M | Net income 2024 * | -151M -14.12M | EV / Sales 2023 | - |
Net cash position 2023 * | 388M 36.33M | Net cash position 2024 * | 274M 25.59M | EV / Sales 2024 * | 13.5 x |
P/E ratio 2023 |
-4.4
x | P/E ratio 2024 * |
-11.1
x | Employees | 24 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 86.02% |
Latest transcript on Vicore Pharma Holding AB
1 day | -1.60% | ||
1 week | -5.02% | ||
Current month | +4.68% | ||
1 month | +2.22% | ||
3 months | +2.07% | ||
6 months | -3.02% | ||
Current year | +4.09% |
Managers | Title | Age | Since |
---|---|---|---|
Ahmed Mousa
CEO | Chief Executive Officer | 40 | 23-09-08 |
Hans Jeppsson
DFI | Director of Finance/CFO | - | 16-12-31 |
Elin Rosendahl
CTO | Chief Tech/Sci/R&D Officer | - | 20-11-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 57 | 17-12-31 | |
Director/Board Member | 66 | 17-12-31 | |
Michael Buschle
BRD | Director/Board Member | 64 | 22-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 14.68 | -2.13% | 132 500 |
24-03-27 | 15 | +2.32% | 136,665 |
24-03-26 | 14.66 | -2.14% | 134,876 |
24-03-25 | 14.98 | -2.73% | 109,498 |
24-03-22 | 15.4 | -0.90% | 115,795 |
Delayed Quote Nasdaq Stockholm, March 28, 2024 at 05:30 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.09% | 158M | |
+2.56% | 108B | |
+10.02% | 104B | |
+7.57% | 23.66B | |
-11.91% | 22.1B | |
-3.29% | 19.71B | |
-35.98% | 18.2B | |
-14.02% | 16.19B | |
+4.61% | 13.72B | |
+35.05% | 12.22B |